title: Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
abstract: The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson's disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson's disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson's Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p < 0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.
authors.affiliation: Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculté de Médecine, Université de Rennes I, Rennes, France.Herve.Allain@univ-rennes.fr
authors.forename: H
authors.initials: H
authors.lastname: Allain
authors.forename: A
authors.initials: A
authors.lastname: Destée
authors.forename: H
authors.initials: H
authors.lastname: Petit
authors.forename: M
authors.initials: M
authors.lastname: Patay
authors.forename: S
authors.initials: S
authors.lastname: Schück
authors.forename: D
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.forename: P
authors.initials: P
authors.lastname: Le Cavorzin
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D008090:Lisuride